Galectin-3 in acute myocardial infarction: from molecular mechanisms to clinical translation

Galectin-3 occupies a critical position at the intersection of AMI pathogenesis, diagnosis, and therapy. Targeting the galectin-3 pathway represents a promising therapeutic strategy to improve post-AMI outcomes, although its clinical translation requires further investigation. This review underscores the potential of integrating galectin-3 assessment and inhibition into future AMI management strategies.